Puneet Souda
Stock Analyst at Leerink Partners
(1.60)
# 3,429
Out of 5,056 analysts
218
Total ratings
48.59%
Success rate
-0.89%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $576.03 | +0.69% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $74.11 | +5.25% | 8 | Oct 21, 2025 | |
| GH Guardant Health | Maintains: Outperform | $70 → $75 | $95.57 | -21.52% | 6 | Sep 25, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $8.39 | +90.70% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $5.35 | +124.30% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $5.62 | +42.35% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $10.41 | -13.54% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $6.63 | +216.74% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $38.76 | +3.20% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $213.65 | -29.79% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $376.63 | -0.43% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $33.55 | +4.32% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $143.84 | +0.81% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $225.51 | +33.03% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $121.97 | +104.97% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $58.15 | +89.17% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $69.68 | +7.63% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $153.06 | +30.67% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.66 | +391.80% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.61 | +272.67% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $26.00 | +15.38% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $42.66 | +103.94% | 13 | May 5, 2022 |
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $576.03
Upside: +0.69%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $74.11
Upside: +5.25%
Guardant Health
Sep 25, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $95.57
Upside: -21.52%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $8.39
Upside: +90.70%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $5.35
Upside: +124.30%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $5.62
Upside: +42.35%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $10.41
Upside: -13.54%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $6.63
Upside: +216.74%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $38.76
Upside: +3.20%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $213.65
Upside: -29.79%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $376.63
Upside: -0.43%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $33.55
Upside: +4.32%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $143.84
Upside: +0.81%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $225.51
Upside: +33.03%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $121.97
Upside: +104.97%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $58.15
Upside: +89.17%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $69.68
Upside: +7.63%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $153.06
Upside: +30.67%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.66
Upside: +391.80%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.61
Upside: +272.67%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $26.00
Upside: +15.38%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $42.66
Upside: +103.94%